How a specific signaling pathway affects muscle stem cell function
Epigenetic control of muscle stem cell function by PASK-Wdr5 signaling
This study is looking at how certain proteins help muscle stem cells work better, which could lead to new treatments for muscle diseases, so people with muscle-wasting conditions might get improved care in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10766126 on NIH RePORTER |
What this research studies
This research investigates the role of a signaling pathway involving PASK and Wdr5 in regulating muscle stem cells, which are crucial for muscle repair and maintenance. By understanding how these cells respond to their environment and the signals they receive, the research aims to uncover new therapeutic strategies for muscle-related diseases. The study focuses on the epigenetic mechanisms that control muscle regeneration and homeostasis, particularly how certain proteins influence gene expression in muscle stem cells. Patients may benefit from insights that could lead to improved treatments for muscle wasting and related conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who may be experiencing muscle-related issues or conditions that affect muscle function.
Not a fit: Patients with acute muscle injuries that do not involve stem cell dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance muscle regeneration and combat muscle wasting diseases.
How similar studies have performed: Previous research has shown promise in understanding muscle stem cell signaling, indicating that this approach could yield significant insights.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Kikani, Chintan K — University of Kentucky
- Study coordinator: Kikani, Chintan K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.